CB2 Insights Announces Delay in Filing Annual Financial Statements

TORONTO, June 15, 2020 (GLOBE NEWSWIRE) -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF) announces that it has been delayed in filing its annual financial statements (the “Annual Financial Statements”) and associated management discussion and analysis (“MD&A”) for the year-ended December 31, 2019, which were required to be filed on June 15, 2020.

The Company now expects to file the Annual Financial Statements and related MD&A on or before Thursday June 18, 2020.

The delay in filing occurred due to the Company’s auditors request for additional time to finalize its review of the Company’s financial information and to complete its normal audit procedures.

As a result of the above, the Company has rescheduled its earnings call to Friday June 19, 2020 at 9:00 a.m. (EST).

Conference call details:
DATE:	Friday, June 19, 2020
TIME:	9:00 a.m. (EST)
US/Canada Toll Free Dial In:	1-800-319-4610
Toronto Local Dial In:	1-416-915-3239
International Toll:	1-604-638-5340
CALL NAME:	CB2 Insights Earnings Call

The Company continues to see strong growth in execution of its business plan. On an unaudited basis, the Company continues to illustrate profitability in Q2 2020. The Company has also strengthened its balance sheet with cash from operations, and the receipt of relief funds available to its US medical services business due to the COVID-19 pandemic.

About CB2 Insights

CB2 Insights (CSE:CBII) CB2 Insights is a healthcare services and technology company, working to positively impact patient health outcomes. Our mission to mainstream alternative health treatments into traditional healthcare by recognizing the need for patient treatment diversity, and the impacts of integrating alternative and conventional medicine. The Company works primarily to roster and treat patients who are seeking alternative treatments due to the ineffectiveness of conventional medicine, and the inability to find support through their existing care network, or in some cases, inability to access a primary care network. Medical services offered by the Company are defined as Integrative medicine, where we work to understand the real world evidence for the safety, impact and effectiveness of medical treatments including plant based medicines that often lack sufficient research and therefore adoption by conventional healthcare providers.